2022
Mitochondrial fitness and cancer risk
Kossenkov AV, Milcarek A, Notta F, Jang GH, Wilson JM, Gallinger S, Zhou DC, Ding L, Ghosh JC, Perego M, Morotti A, Locatelli M, Robert ME, Vaira V, Altieri DC. Mitochondrial fitness and cancer risk. PLOS ONE 2022, 17: e0273520. PMID: 36223343, PMCID: PMC9555630, DOI: 10.1371/journal.pone.0273520.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaSenescence-Associated Secretory PhenotypeIndependent patient cohortsPoor patient outcomesAggressive disease variantFolfirinox failureLocal inflammationPatient cohortDuctal adenocarcinomaPatient outcomesPatient riskMultiple malignanciesCancer riskMitochondrial fitnessSecretory phenotypeGene signatureHallmarks of cancerMetastatic propensityNormal tissuesHuman tumorsInterferon SignalingTumorsInner membrane mitochondrial proteinMalignancyMolecular signatures
2019
Syntaphilin Is a Novel Biphasic Biomarker of Aggressive Prostate Cancer and a Metastasis Predictor
Hwang MJ, Bryant KG, Seo JH, Liu Q, Humphrey PA, Melnick MAC, Altieri DC, Robert ME. Syntaphilin Is a Novel Biphasic Biomarker of Aggressive Prostate Cancer and a Metastasis Predictor. American Journal Of Pathology 2019, 189: 1180-1189. PMID: 31079810, PMCID: PMC6560381, DOI: 10.1016/j.ajpath.2019.02.009.Peer-Reviewed Original ResearchConceptsProstate cancerTumor bulkInvasive frontHigh Gleason grade prostate cancerLocalized prostate cancerGrade prostate cancerAggressive prostate cancerCell proliferationKi-67 labelingTumor cell proliferationMetastasis predictorMetastatic diseaseDistant metastasisGleason gradeAccessible biomarkersProstate tumorsMetastatic potentialNovel markerCancerBiphasic patternProliferative rateHigh expressionOxidative metabolismReduced levelsTumors